Name | Value |
---|---|
Revenues | 152.0K |
Cost of Revenue | 257.0K |
Gross Profit | -105.0K |
Operating Expense | 3,576.0K |
Operating I/L | -3,681.0K |
Other Income/Expense | 34.0K |
Interest Income | 0.0K |
Pretax | -3,647.0K |
Income Tax Expense | -218.0K |
Net Income/Loss | -3,429.0K |
Vyant Bio, Inc. is a biotechnology company specializing in drug discovery for complex neurodevelopmental and neurodegenerative disorders. Their CNS drug discovery platform integrates human-derived organoid models, scaled biology, and machine learning to identify small molecule clinical candidates for rare CNS genetic disorders such as Rett Syndrome, CDKL5 deficiency disorders, and familial Parkinson's disease. The company's collaboration agreement focuses on discovering drugs for Parkinson's Disease treatment. Vyant Bio, Inc. generates revenue through drug discovery, development, and potential commercialization of novel and repurposed small molecule drugs for rare CNS genetic disorders.